My invention and product may offer solution. It is new paradigm of mechanical ventilation, I call it Mechanical Ventilation 2.0.
Postulated benefits of the technology we want to develop and get to the market.
Better clinical outcomes, including:
- decreased mortality, improved survival
- prevention of ventilator associated pneumonia,
- no need to implement permissive hypercapnia in ARDS,
- ability to independently set goal pO2 and pCo2,
- independence on type of pathogen (new viral strains, toxic warfare agents- it should work independently on the pathogen strain or type, likely no need to study for each another strain, unlike vaccines),
- down-stream benefits (less antibiotics use, less clostridium difficile infections)
Better financial outcomes:
- shorter “on-ventilator” time,
- shorter ICU stay,
- shorter hospital stay,
- faster recovery,
- shorter “back-to-work” time,
- less healthcare resources utilization,
- possibly higher reimbursement in institutions with better clinical outcomes (i.e. due to - less clostridium difficile infection)
Safer for staff:
- separation of inspiratory and exploratory lumens prevents release of pathogens into the patient room / hallway / ICU atmosphere, as patients can be suctioned using only inspiratory lumens, the expiatory lumens can be used as suctioning tubes anyways in a close-circuit fashion
No staff steep learning curve needed:
- similar procedures to place patient on ventilator, and off ventilator
- similar concept about ventilator management
- comparable price to current mechanical ventilators
with adapters, which concepts are within our Intellectual Property Portfolio, technology can be easily extended to currently used ventilators
3D animation demo:
https://www.youtube.com/watch?v=2TBANTEuh24
3D animation of comparison between currently used mechanical ventilation and my invention:
https://www.youtube.com/watch?v=EspHpSp20QE
USPTO patent (US 2022-0072250) as allowed for download and review:
https://endlessmedical.com/wp-content/uploads/2022/03/VENTILATOR-SYSTEM-WITH-MULTIPLE-AIRFLOW-CONTROL-LUMENS-US_20220072250_A1_I.pdf
USPTO and PTC patent applications for download and review:
https://endlessmedical.com/wp-content/uploads/2021/06/US-Patent-Application-17-345994-c.pdf
Invention presented here can hypothetically (more detailed and in technical terms):
- improve outcomes by increasing oxygenation especially with low tidal volume ventilation, i.e. ARDS with high PEEP
- improve ARDS outcomes, by increasing Co2 clearance and possibly avoiding the need for permissive hypercapnia while using ARDS-net protocol
- improve chances of recovery by elimination of toxins, bacteria, or viruses (i.e. covid) from the lungs by assuring continuous flow within the airways towards the expiratory lumens
- potentially functionally isolate portions (i.e. left vs. right) of the lungs, to limit the cross contamination of toxins, bacteria, or viruses (i.e. covid)
Łukasz Kiljanek M.D. is a board certified in Internal Medicine, Nephrology and Hypertension. Experienced in Intensive care, Pulmonary, Chest surgery and Cardiology. Clinical researcher, AI and data mining, and programmer
We are the concept / basic prototype level.
The purpose of this description is to illustrate the concepts, unproven yet benefits of and the fundamentals of the invention “Mechanical Ventilation v2.0” in order to find partners / mentors and sponsors who might be interested in further development of the technology, or buyers, who might be interested in purchasing the IP.
Why is this important?
-each year, before covid, there were about ~ 2 million ventilated Intensive Care Units (ICU) patients in USA
-ventilated patients usually have high mortality (50%) and for some diseases even higher (COVID 26-97%, H1N1 influenza and others 25-46%)
-mechanical ventilation and complications renders ~ 2.5 x costs $ of ICU stay as of 2005
-patients on ventilators consume very high resources with high morbidity, with longer ICU and hospital stays
-mechanical ventilation now 50 + years, with no major developments in its foundations
]
Main technical features of Mechanical Ventilation 2.0:
-separate inspiratory and expiratory lumen(s) prevents re-breathing of contaminated air and allow for functional separation of lungs portions, which can prevent cross-contamination of i.e. infected air from sick left lung to healthy or healthy yet right lung
-continuous variable flows via inspiratory and expiratory lumens provide clearance of dead space and suspended within diseases causative agents (i.e. covid virions, toxins), allowing for full recovery, and eliminates reinfection of recovered alveoli / pneumocytes
-more inflow via inspiratory lumens than outflow via expiratory lumens results in inspiration
-more outflow via expiratory lumens than inflow via inspiratory lumens results in expiration
-operator can independently adjust the amount of delivered O2 and cleared amount of CO2
benefit in ARDS, no need to implement permissive hypercapnia with effective respiratory acidosis benefit in severe COPD exacerbation with massive CO2 retention
-adapter allowing to use some benefits of our technology with existing “vents” included in our Intellectual Property portfolio
What we have accomplished until now:
-secured USPTO non provisional patent allowance with optional continuation.
-3D animations for explanation done.
-we have a simplified model / prototype.
-we proved some concepts and some feasibility subjectively
Why we need investors, and how much money we need to raise:
Financing (300 000$) to build a prototype of ventilator and endotracheal tubes, with “lungs” model and protecting international Intellectual Property protection.
We need prototype and lungs model to performer rigorous, quantitative and objective proof of concept, accurate estimation of particulate clearance from airways in various ventilatory modes and with various inspiratory / expiratory lumens configuration.
We would like to form LLC, where investors would acquire shares (ultimately).
Investors are welcome to serve as mentors and part of the team, this is negotiable and we are opened to all offers.
We would also consider much less monetary investment for shares, from person with skills, time and knowledge to become part of the team.
Alternatively, the invention and entire IP is for sale for 250 000 000$, this is negotiable and we are opened to all offers.
No offers, deals, sales, acquisitions are valid, until they are expressed in writing and signed by both parties in the presence of notary public.
Mentorship and networking appreciated. Help us in:
Developing the proof of concept prototype, collaboration, quantitative and subjective testing of the concept, securing more funding for further development, and then animal, clinical studies and marketing.
Please see the following videos for more details and explanations :
https://www.youtube.com/watch?v=2TBANTEuh24
https://www.youtube.com/watch?v=QIOpsy3qnK4
Comparison of Contemporary used Mechanical Ventilation and my invention for sale, Mechanical Ventilation 2.0:
https://youtu.be/EspHpSp20QE
USPTO patent (US 2022-0072250) as allowed for download and review:
https://endlessmedical.com/wp-content/uploads/2022/03/VENTILATOR-SYSTEM-WITH-MULTIPLE-AIRFLOW-CONTROL-LUMENS-US_20220072250_A1_I.pdf
USPTO and PTC patent applications for download and review:
https://endlessmedical.com/wp-content/uploads/2021/06/US-Patent-Application-17-345994-c.pdf
Ready to Ask For Funding for your company?
Post a Funding Request